Sai Parenterals: Investor press release on standalone and consolidated unaudited financial results for the quarter ended 30th…
Sai Parenterals (SAIPARENT) filed a disclosure titled "Investor press release on standalone and consolidated unaudited financial results for the quarter ended 30th September, 2026". The company is valued at about ₹2,306 crore.
What happened
Sai Parenterals (SAIPARENT) filed a disclosure with the exchanges on 1 November 2026 at 06:18 PM titled "Investor press release on standalone and consolidated unaudited financial results for the quarter ended 30th September, 2026".
Company snapshot
Sai Parenterals is a small-cap company, with a market value of about ₹2,306 crore.
The stock last traded at ₹522, against a 52-week range of ₹400–₹706 (26.1% below the high).
Before this filing the shares had moved −1.4% over the month and −5.9% over three months. Average daily turnover over the last 20 sessions was about ₹7.28 crore.
Promoters held 51.16% at the end of Q1 FY27. Foreign institutions owned 4.03% and domestic institutions 8.53%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q3 FY26 | 96 | -6.7 | -2.22 |
| Q4 FY26 | 198 | 13.2 | 4.02 |
| Q1 FY27 | 179 | 7.9 | 1.79 |
What history shows
This is not the company's first results disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
Market-wide, 10,125 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 1 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.